CAMBRIDGE, Mass.--(BUSINESS WIRE)--
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced that Andrew J. Hirsch has joined the company as its Chief Financial Officer. Mr. Hirsch brings nearly twenty years of financial leadership and strategic management experience.
We are very pleased to welcome Andrew to the BIND team, said Scott Minick, President and Chief Executive Officer of BIND Biosciences. Andrew has been an outstanding performer in the biotechnology industry, including major accomplishments with high-growth companies in financing, M&A transactions, strategic planning and investor relations, and his experience will add additional strength to our management team as our growth accelerates.
This is an exciting time to be joining BIND as BIND-014, the companys lead Accurin drug candidate continues to show promise as an important medicine for solid tumors as it advances in the clinic and the companys platform for developing highly selective targeted therapeutics is generating a pipeline of important medicines for patients., said Andrew Hirsch.
Prior to joining BIND, Mr. Hirsch was Chief Financial Officer at Avila Therapeutics until its acquisition by Celgene Inc. in March 2012. Previously, Mr. Hirsch served in roles of increasing responsibility during his nearly ten year tenure at Biogen Idec, most recently as Vice President, Corporate Strategy and M&A, where he played a key role in developing a new strategy for the company and evaluating M&A opportunities. Prior to that, Mr. Hirsch held various positions in the finance organization including leading the companys Business Planning and Investor Relations functions. Prior to joining Biogen Idec, Mr. Hirsch led business development for a software start-up company and spent several years in management consulting at both Stern Stewart & Co. and The Parthenon Group. He holds a Masters of Business Administration from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania.
About BIND Biosciences
BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BINDs Medicinal NanoengineeringTM platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's lead product candidate, BIND-014, is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.
BIND is backed by leading investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of Harvard Medical School. For more information, please visit the company's web site at http://www.bindbio.com.
Link:
BIND Biosciences Appoints Andrew J. Hirsch as Chief Financial Officer